GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...
GSK plc (GSK, GSK.L), on Thursday, announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head ...
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...
On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...
GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...
UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...
TipRanks on MSN1d
GSK downgraded to Hold from Buy at Deutsche BankDeutsche Bank analyst Emmanuel Papadakis downgraded GSK (GSK) to Hold from Buy with a price target of 1,350 GBp, down from 1,700 GBp. Published ...
LONDON, UK I 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from a planned interim analysis of the DREAMM-7 ...
The pharma group reported top-line results from the DREAMM-7 study this morning, showing a greater benefit for Blenrep (belantamab mafodotin) compared to Genmab and Johnson & Johnson’s anti-CD37 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback